BenevolentAI
Employs an artificial intelligence platform to discover novel therapies for complex diseases.
What they do
BenevolentAI builds an end to end platform that ingests massive biomedical data to generate scientific insights. Their software helps research scientists identify target diseases, design new drug molecules, and predict patient responses to accelerate clinical development.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Public
- Headquarters
- London, United Kingdom
- Region
- Europe
- Founded
- 2013
- Total funding
- $300M raised
Notable investors: Temasek Holdings, Lansdowne Partners, Woodford Investment Management.